Sci-B-Vac® Late-Breaker Oral Presentation at EASL 2020

By August 31, 2020No Comments

Data from the Phase 3 program evaluating Sci-B-Vac®, VBI’s company’s tri-antigenic prophylactic hepatitis B (HBV) vaccine, was presented in a late-breaker oral presentation at The Digital International Liver CongressTM 2020 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL). During the presentation, Adam Finn, M.D., Ph.D., Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, discussed the successfully-met primary endpoint of CONSTANT – demonstration of consistency of immune response as measured by the geometric mean concentration (GMC) of hepatitis B antibodies (anti-HBs titers) across three consecutively-manufactured lots of vaccine.